Business Context and Reporting Period
This Form 6-K filing by Psyence Biomedical Ltd. covers the month of February 2026, with the report dated March 2, 2026. The filing details a settlement-related loan agreement, the implementation of a share put option transaction, changes to the Board of Directors, and recent press releases.
Key Financial Metrics and Transactions
- Loan Agreement: The Company's subsidiary, Psyence Biomed II Corp., lent US$251,110.00 to Curiosum Ltd. to facilitate a share purchase under a settlement agreement. The loan bears interest at the Royal Bank Prime rate plus 1% per annum and matures three months from the effective date.
- Share Exchange: The Company issued 1,146,159 common shares to Psyence Labs Ltd. ("PsyLabs") in exchange for US$5,000,000 worth of PsyLabs ordinary shares. No cash consideration was exchanged.
- Ownership Structure: Following the share exchange, PsyLabs beneficially owns approximately 49.98% of the Company's issued and outstanding common shares.
- Liquidity and Debt: The filing does not provide consolidated revenue, profit, or cash flow statements. The US$251,110 loan is a short-term asset for the Company, with repayment contingent on the Borrower's share sale proceeds.
Material Changes Versus Prior Period
- Capital Structure: Significant dilution occurred with the issuance of 1,146,159 new shares, resulting in PsyLabs holding nearly 50% of the company.
- Board Composition: Seth Feuerstein resigned from the Board of Directors effective February 20, 2026. Sashank Pillay was appointed to fill the vacancy and serves on the Audit, Compensation, and Nominating and Corporate Governance Committees.
- Settlement Progress: The Company executed a loan to a third party to finalize a previously announced settlement with the KAOS Group regarding the sale of 50,220 common shares.
Outlook, Risks, and Management Commentary
- Management Rationale: The appointment of Mr. Pillay was driven by his extensive experience in cultivation, production, and regulatory frameworks for controlled substances, aligning with the Company's investment in PsyLabs.
- Risks and Contingencies: The loan to Curiosum Ltd. carries repayment risk, as it is secured by the proceeds of a share sale. The filing notes the loan is a legally binding obligation and will not be forgiven.
- Regulatory Compliance: The share issuance relied on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and/or Regulation S.
Key Facts for Investor Verification
- Verify the current trading price and 30-day VWAP of Psyence Biomedical Ltd. common shares to assess the valuation of the 1,146,159 shares issued to PsyLabs.
- Confirm the status of the share sale by Curiosum Ltd. to ensure the US$251,110 loan is repaid as scheduled.
- Review the full text of the Loan Agreement (Exhibit 10.1) for specific default clauses and covenants.
- Assess the impact of PsyLabs' 49.98% ownership stake on future corporate governance and strategic direction.